CC
RGN

Capital Counsel’s REGENERX BIOPHARMACEUTICALS RGN Stock Holding History

Capital Counsel’s Portfolio RGN Stock Details RGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-110,000
Closed -$8K – 149
2013
Q3 		$8K Buy
110,000
+100,000
+1,000% +$7.27K ﹤0.01% 135
2013
Q2 		$1K Buy
+10,000
New +$1K ﹤0.01% 125

Other funds holding RGN

DBIA
Dumont & Blake Investment Advisors Princeton, New Jersey $400M AUM 21.87% 1-Year Est. Return

Capital Counsel's RGN Position: Q4 2013 in Review

Capital Counsel sold out of REGENERX BIOPHARMACEUTICALS (RGN) in Q4 2013, closing a stake of 110,000 shares — an estimated $8K sold.

Capital Counsel first reported a position in RGN in Q2 2013 and held it in 2 quarters. The position peaked at $8K in Q3 2013. 1 fund tracked by Wall St. Rank holds RGN as of Q4 2013.

  • Capital Counsel reported no remaining REGENERX BIOPHARMACEUTICALS position as of Q4 2013 after selling out during the quarter.
  • Capital Counsel sold 110,000 REGENERX BIOPHARMACEUTICALS shares in Q4 2013, an estimated $8K.
  • Capital Counsel first reported a position in REGENERX BIOPHARMACEUTICALS in Q2 2013 and held it in 2 quarters.
  • Capital Counsel's REGENERX BIOPHARMACEUTICALS position peaked at $8K in Q3 2013.
  • 1 fund tracked by Wall St. Rank held REGENERX BIOPHARMACEUTICALS as of Q4 2013.

Based on Capital Counsel's 13F filing for Q4 2013, filed 12 Feb 2014.